Avanza

Quick links to important sections

Avanza

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Avanza

Property Description
Active ingredient Mirtazapine
Form Tablet (Film-coated, Orally Disintegrating), Oral Solution
Pharmacological class Atypical Antidepressant / NaSSA
Common use Supporting emotional stability and mood
Origin Synthetic (Chemically synthesized)

What is the Active Substance in Avanza?

Avanza is a specific brand name for a prescription-only medicinal product containing the single active ingredient mirtazapine. This substance is a synthetic compound with a complex tetracyclic chemical structure, guaranteeing precise purity and stability. Mirtazapine is an established compound used in clinical practice.

Mirtazapine is available for oral administration in several forms, which include the standard film-coated tablet and the rapidly dissolving orally disintegrating tablet, as well as an oral solution or liquid. The composition is strictly limited to this active component and necessary pharmaceutical excipients, establishing it as a single-ingredient product. The brand Avanza is particularly recognized in regions such as Australia and the Netherlands.

Mirtazapine's Unique Pharmacological Class (NaSSA)

Mirtazapine is classified pharmacologically as an atypical antidepressant and, more specifically, as a Noradrenergic and Specific Serotonergic Antidepressant (NaSSA). It is indicated for the treatment of major depressive disorder. Mirtazapine's distinct receptor binding profile allows for its unique therapeutic role as a second-generation antidepressive agent. This means the medicine operates differently than many common options, which is clinically recognized for offering a varied pathway for individuals seeking mood support.

The medicine achieves its effect through a unique dual mechanism that enhances the activity of both the serotonin and noradrenaline neurotransmitter systems simultaneously. This action, which also involves strong Histamine H1 antagonism, differentiates it from other common types, making it particularly useful when a patient's condition involves co-occurring sleep disturbance.

Regulatory References

  1. FDA Mirtazapine Label
  2. MedlinePlus Mirtazapine Information

What side effects are possible with Avanza?

Possible Side Effects and Safety Information

The safety profile of Avanza (mirtazapine) is officially classified based on the frequency and the physiological systems affected, derived from regulatory clinical studies and post-marketing surveillance. This information strictly describes officially documented adverse reactions.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by frequency, which dictates the likelihood of their occurrence as established in regulatory documents:

  • Very Common (ge 10%): These are the most frequent documented effects and include somnolence (drowsiness), increased appetite, weight gain, dry mouth, and constipation.
  • Common (1-10%): Reactions listed in this category include dizziness, asthenia (weakness), headache, and peripheral edema.

System-Organ Classes and Serious Reactions

Adverse effects are documented across various physiological systems. The official label notes effects on the Nervous System (somnolence, tremor), Metabolism and Nutrition (weight gain, increased appetite), and Blood and Lymphatic System.

Serious Adverse Reactions officially listed in regulatory documents include the rare but severe risk of Agranulocytosis (a severe decrease in white blood cells) and the potential for Serotonin Syndrome, a potentially life-threatening condition associated with changes in mental status and neuromuscular activity. Serious Severe Cutaneous Adverse Reactions (SCAR) are also documented.

Population and Time-Related Safety

Specific safety considerations exist for certain groups. Mirtazapine is not approved for the pediatric population (under 18) due to the documented increased risk of suicide-related behaviors in clinical trials. Caution is also noted for older adults and individuals with renal or hepatic impairment, as drug clearance is reduced.

Time-related patterns show that somnolence is most common at the start of treatment. Abrupt cessation of use, particularly following long-term therapy, is associated with documented discontinuation symptoms (e.g., dizziness, headache, anxiety).

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Avanza (mirtazapine) overdose primarily documents effects on the Central Nervous System (CNS) and the Cardiovascular System.

Documented CNS presentations include somnolence, disorientation, impaired memory, and confusion. More serious or life-threatening outcomes reported post-marketing involve Tachycardia, QT prolongation, Ventricular tachycardia, Torsades de Pointes, and Sudden death, especially in cases of mixed overdoses.

Required Emergency Action

Since no specific antidote is known, management is entirely symptomatic and supportive. This approach requires close monitoring of vital signs and cardiac rhythm, specifically including ECG monitoring. Immediate medical help must be sought in the event of any suspected overdose. Immediately call Emergency Services (911/equivalent) if the affected individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened (unresponsive).

Population-Specific Considerations

To mitigate the risk of overdose, only a limited quantity should be dispensed to patients with an increased risk of suicide. Furthermore, caution is officially advised when prescribing to patients with known cardiovascular disease or a family history of QT prolongation, due to heightened cardiac risk.

Therapeutic Uses of Avanza

What Avanza Treats: Main Uses and Benefits

Avanza is commonly used for managing conditions characterized by periods of heightened symptoms related to Major Depressive Disorder (MDD), managing the episodic or persistent emotional distress associated with the condition. As a treatment for depression, the medication is applied across domains where additional symptomatic support is needed to address core depressive manifestations, such as persistent low mood and sadness. The therapeutic benefit is primarily the support of emotional stability, and assists with maintaining functional stability.

Avanza is also commonly used in conditions where depressive illness is accompanied by sleep disturbance—such as difficulty falling asleep or frequent awakenings. This application provides support that helps ease the overall symptom burden, contributing to a more restful sleep cycle. Furthermore, the medication is relevant for managing neurovegetative symptoms that may include loss of appetite and associated low body weight. It may assist with appetite, which is considered relevant in situations where patients experience nutritional deficits linked to their mood disorder, supporting general well-being.


Key Use: Relief for Neurovegetative Symptoms The medication is commonly used when symptoms related to systemic imbalance include both low mood and loss of appetite or sleep disruption. This supports general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Avanza?

Avanza (mirtazapine) eligibility is strictly defined by government regulatory agencies, establishing specific patient groups who can and cannot use the medicine under labeled conditions.


Populations for Whom Use is Allowed

The medicine is officially indicated for the treatment of Major Depressive Disorder in adult patients (18 years and older).

Absolute Contraindications (Do Not Use)

Avanza must not be used by patients with a known hypersensitivity to mirtazapine or any of its components. It is strictly contraindicated for any patient concurrently taking a Monoamine Oxidase Inhibitor (MAOI), or within 14 days of discontinuing an MAOI.

Restricted and Conditional Use

Regulatory labels require caution for the following populations:

  • Age-Related Eligibility: The medicine is not approved and safety is not established for use in children and adolescents under 18 years. Caution is indicated for elderly patients due to reduced drug clearance.
  • Organ Function: Caution is required in patients with moderate to severe hepatic or renal impairment, as clearance is decreased, and a dose change may be necessary.
  • Comorbidities: Patients with a history of mania or hypomania must be screened prior to treatment. The orally disintegrating formulation contains phenylalanine, which is a restriction for patients with Phenylketonuria (PKU).
  • Reproductive Status: Use during pregnancy is restricted to when it is clearly needed. Caution must be exercised when administered to a nursing woman.

What should I know about interactions with other medicines?

Avanza Interactions with other medicines and products

This section outlines interactions for mirtazapine, the active ingredient in Avanza, as documented in official government regulatory information.


Prohibited Combinations and Timing

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated. This prohibition includes the antibiotic linezolid and intravenous methylene blue due to their documented MAOI activity. A mandatory 14-day separation is required between stopping an MAOI and starting mirtazapine, or vice versa.


Pharmacokinetic and Pharmacodynamic Interactions

Interactions are structured around metabolic clearance and additive effects:

  • Exposure Modification (CYP3A4): Strong CYP3A Inducers (e.g., carbamazepine, phenytoin, rifampicin) decrease mirtazapine plasma levels by increasing clearance. Conversely, strong CYP3A Inhibitors (e.g., ketoconazole, clarithromycin) and cimetidine reduce clearance, increasing mirtazapine plasma levels.
  • Serotonergic and CNS Effects: Co-administration with other serotonergic drugs (e.g., SSRIs, triptans, the herbal product St. John's Wort) increases the documented risk of Serotonin Syndrome. Mirtazapine also enhances the effects of other CNS depressants, including alcohol and benzodiazepines.

Population-Specific Notes

Official labeling notes that mirtazapine clearance is decreased in patients with hepatic impairment or moderate to severe renal impairment, which may amplify the clinical significance of these documented interactions due to heightened exposure.

Mechanism of Action

Avanza is a compound that acts as an inhibitor of the enzyme farnesyl pyrophosphate synthase (FPPS) within osteoclasts. The mechanism initiates when Avanza selectively binds to the mineral component of bone. Osteoclasts internalize the compound during the resorption process. Once inside, Avanza interferes with the mevalonate pathway by inhibiting FPPS, which is essential for the production of farnesyl and geranylgeranyl pyrophosphates. These molecules are required for the prenylation of small signaling proteins, such as GTPases. By preventing prenylation, Avanza disrupts the cell signaling, morphology, and cytoskeletal integrity of the osteoclast, effectively modulating its resorptive function. This cellular action alters the balance of bone remodeling. The compound is retained in the bone matrix, enabling its extended interaction with osteoclasts.

Dosage and Administration Information

How to Use Avanza

Avanza (mirtazapine) is utilized exclusively via the oral route and is typically administered as a once-daily dose, often taken in the evening before bedtime. The medicine is available as film-coated tablets, orally disintegrating tablets (ODT), and an oral solution.

The administration schedule begins with a standardized starting dose of 15 mg per day for adults. Based on the individual's clinical needs, the daily dosage is then adjusted incrementally, or titrated, over intervals of one to two weeks. The established maintenance range is 15 mg to 45 mg per day, with 45 mg representing the maximum recommended daily amount. The drug can be taken independently of meals.

Administration Forms and Use Patterns

Form Type Administration Principle Duration and Adjustment Principle
Film-coated Tablet Swallowed whole with fluid. Treatment typically continues for four to six months after symptoms resolve.
ODT (Orally Disintegrating) Placed on the tongue to dissolve without water; hands must be dry when handling. Dose changes, including the necessary gradual reduction (tapering) to end treatment, are structured over several weeks.

For specific populations, dose adjustments are necessary; for instance, a lower maintenance dose is generally advised for individuals with hepatic or renal impairment. In the event that a once-daily dose is missed, it should not be taken the following morning, and the regular night-time schedule should be resumed that evening.

Recent Clinical Evidence

Research evidence / Overview of Studies for Avanza (Mirtazapine)

Avanza was studied for its use in individuals with Major Depressive Disorder (MDD). The primary research base includes numerous short-term, placebo-controlled clinical trials (RCTs). These studies typically involved adult outpatients and examined how symptoms change over a defined period, usually lasting six to eight weeks.

The primary clinical trials examined outcomes capturing phases of heightened symptom activity, measured using standardized scales. Research explored whether patients reached a defined level of response (a reduction in symptom intensity that met trial criteria) or remission (reaching a minimum symptom score).

Examination of Specific Symptom Factors (Sleep and Appetite)

Within the main short-term MDD trials, researchers also examined specific factors related to systemic or functional imbalance, such as sleep disturbance and changes in appetite/body weight. This aspect of the medicine was evaluated in patients where the mood disorder presented with these co-occurring symptoms.

Studies report how symptoms evolved in the observed populations across these specific domains. For instance, the acute MDD trials consistently documented patterns related to measurements of body weight increase and measurements related to sleep parameters and duration were also frequently recorded. However, there is no large-scale controlled research evaluating the medicine as a stand-alone treatment for primary sleep or appetite disorders, separate from MDD.

Evidence for Maintenance of Stability and Relapse Prevention

Research for maintenance treatment focuses on conditions presenting with cycles of stability and flare-ups. This aspect was studied for its role in maintaining stability after patients achieved a positive response to initial therapy. This research consists of medium-term continuation trials where adult patients were observed in a controlled setting for periods that sometimes lasted up to 40 weeks or more.

Limitations and Uncertainties in the Research Landscape

It is important to understand the evidence highlights what is known — and what is still uncertain. The research is focused heavily on short-term symptom reduction, meaning there is limited information for long-term outcomes regarding functional recovery or overall quality of life beyond preventing symptom relapse. Furthermore, the evidence quality varies across studies, and comparative evidence against a wide range of other antidepressant treatments remains limited.

Key Studies & References

  1. Mirtazapine Drug Information - MedlinePlus

Frequently Asked Questions (FAQ)

Common questions about Avanza (FAQ)


Q: How quickly does Avanza start to work after the first dose?

Studies and official information indicate that physical symptoms of depression, such as improvements in sleep, energy, and appetite, may begin within the first one to two weeks of starting treatment. However, the full therapeutic response on mood may take longer to develop, according to clinical documentation.


Q: Can I take Avanza if I am already taking herbal supplements?

Official product information advises against the co-administration of Avanza with certain herbal products, specifically St. John's Wort. This combination is documented to increase the risk of side effects, including the potentially serious condition known as Serotonin Syndrome. Regulatory guidance emphasizes the importance of disclosing all supplements to a healthcare provider.


Q: What kind of monitoring is usually recommended when taking Avanza?

Official guidelines advise monitoring for a worsening of depression and the emergence of suicidal thoughts or behaviors, particularly when treatment is started or the dose is changed. Additionally, official guidelines describe the need for monitoring for signs of infection (like fever or sore throat) due to the documented but rare risk of a severe decrease in white blood cells (Agranulocytosis).


Q: What kind of mental changes are described as possible with Avanza?

Adverse reactions documented in regulatory sources can include common effects like drowsiness (somnolence) and dizziness, as well as less common effects such as agitation or confusion. Official safety information notes the importance of monitoring for potential worsening of depression, the emergence of suicidal thoughts, or shifts into mania.


Q: What is the difference between Avanza and other depression medicines?

Avanza is classified as a Noradrenergic and Specific Serotonergic Antidepressant (NaSSA), which has a mechanism of action that differs from common Selective Serotonin Reuptake Inhibitors (SSRIs). Research has observed that mirtazapine may be associated with a lower occurrence of sexual side effects compared to some SSRIs, though it is commonly linked to increased appetite and weight gain.


Q: Are there specific symptoms that mean Avanza is not working?

Official safety warnings advise monitoring for a persistent worsening of depression or the emergence of unusual behavior changes. A continued lack of noticeable improvement in associated physical symptoms like sleep or energy within the initial few weeks are conditions noted in official guidance as factors for evaluating the treatment plan.


Q: Can Avanza impact energy levels or motivation?

The medicine is indicated for Major Depressive Disorder, which can include low energy and motivation as symptoms. Official information indicates that improvement in energy levels is one of the positive physical effects that may be noticed in the first couple of weeks of use.


Q: Is there a risk of dependence or addiction with Avanza?

Mirtazapine, the active ingredient in Avanza, is not classified as a controlled substance by the U.S. DEA, suggesting a low potential for abuse or addiction. However, regulatory documents state that discontinuing the medicine, particularly after long-term use, may result in documented discontinuation symptoms (or withdrawal effects).


Q: Does Avanza affect blood pressure or heart rate?

Adverse reactions documented in regulatory sources include orthostatic hypotension—a drop in blood pressure when moving from sitting or lying down to standing—and tachycardia (increased heart rate). Severe changes to heart rhythm or blood pressure may be signs of a serious reaction or overdose.


Q: Does Avanza require special testing before starting use?

Official safety information notes the need to consider the risk of angle-closure glaucoma and the potential need for an eye examination before starting treatment. The need for pre-treatment testing is determined by the healthcare provider based on the individual's profile.


Q: Can Avanza impact sexual function?

Changes in sexual function, such as reduced libido (sex drive) or difficulty achieving orgasm, are recognized side effects of antidepressant treatments. Comparative studies suggest mirtazapine is associated with a lower incidence of these specific side effects than some other classes of antidepressants.


Q: What happens if I accidentally miss a dose of Avanza?

If a dose is missed, regulatory sources note that symptoms associated with discontinuation (e.g., dizziness, anxiety, headache) may occur. The official patient information provides specific instructions on how to manage a missed dose.


Q: Is Avanza typically taken in the morning or at night?

Official labeling recommends that the medicine is generally prescribed as a once-daily dose, taken preferably in the evening at bedtime. This timing is noted in official labeling due to the medicine’s known sedative effects, which can help address sleep disturbances and minimize daytime drowsiness.


Q: What are the official sources for safety information regarding Avanza?

The comprehensive and authoritative safety information for Avanza is contained within the official regulatory documents, such as the FDA Prescribing Information (or Package Insert) and the Health Canada/EMA Product Monograph (or SmPC). These documents are created by government agencies and are continuously updated.


Q: Does Avanza affect the ability to operate a vehicle or machinery?

Because the medicine can commonly cause drowsiness (somnolence) and dizziness, official labeling contains a warning about operating a vehicle or hazardous machinery until the individual knows how the medicine affects their ability to perform such activities.

How should Avanza be stored and disposed of?

Official Storage and Disposal Requirements for Avanza (Mirtazapine)

Avanza must be stored under specific environmental and safety constraints defined in regulatory labeling to maintain its stability.

Storage Conditions

Requirement Official Rule
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep away from excessive heat, moisture, and direct light. Do not freeze.
Container Keep the medicine in its original container, tightly closed. Orally disintegrating tablets (ODT) must be used immediately upon opening the blister pack.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Avanza should be disposed of via a medicine take-back program if one is available. The product must not be discarded by flushing it down the toilet or throwing it away in household wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Avanza found in:

A-Z Index: